304. GRID-GOLPE (Graphic Retrieval and Information Display – General
Optimal Linear PLS Estimation) [Электронный ресурс]. – Режим доступа:
https://www.allacronyms.com/GRID/Graphic_Retrieval_and_Information_
Display.
305.
Grob, A
. Representing dynamic biological networks with multi–scale
probabilistic models [Электронный ресурс]/ A. Grob, B. Kracher, J.M. Kraus
[et al.] // Communications Biology. – 2019. – V. 2, №21. – Режим доступа:
www.nature.com/articles/s42003-018-0268-3.
306.
Gross, G
. Strategies for Enhancing Oral Bioavailability and Brain
Penetration [Текст]: In: The Practice of Medicinal Chemistry, Fourth edition.
Wermuth C.G., Aldous D., Raboisson R., Rognan D., Eds. / G. Gross. –
Amsterdam: Academic Press, 2015. – p. 631–655.
307.
Groussin, L
. Loss of Expression of the Ubiquitous Transcription
Factor cAMP Response Element-Binding Protein (CREB) and Compensatory
Overexpression of the Activator CREMτ in the Human Adrenocortical Cancer
Cell Line H295R [Текст] / L. Groussin, J. F. Massias, X. Bertagna [et al.]// The
Journal of Clinical Endocrinology & Metabolism. – V. 85, №1. – р. 345–354.
308. Guidance for Industry. Bioanalytical Method Validation [Электронный
ресурс]// Food and Drug administration. – 2013. – Режим доступа: http://www.
fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/
ucm368107.
309. Guidance for Industry. Bioequivalence Studies with Pharmacokinetic
Endpoints for Drugs Submitted Under an ANDA [Электронный ресурс]//
Food and Drug administration. – 2013. – Режим доступа: https://www.fda.gov/
downloads/drugs/guidances/ucm377465.pdf.
310. Guidance for Industry. Dissolution Testing of Immediate Release Solid
Oral Dosage Forms [Электронный ресурс]// Food and Drug administration. –
1997. – Режим доступа: http://www.fda.gov/downloads/Drugs/... /Guidances/
ucm070237.pdf.
311. Guidance for Industry. E16 Biomarkers Related to Drug or Biotechnology
Product Development: Context, Structure, and Format of Qualification
Submissions [Электронный ресурс]// Food and Drug Administration. – 2011. –
Режим доступа: https://www.fda.gov/media/81311/download.
312. Guidance for Industry. ICH M4. Оrganization of the CTD [Электрон-
ный ресурс] // U. S. Department of Health and Human Services Food and Drug
Administration. Center for Drug Evaluation and Research (CDER). Center for
Biologies Evaluation and Research (CBER). – 2001. – Режим доступа: https://
www.fda.gov/media/71551/download.
313. Guidance for Industry. SUPAC–IR: Immediate–Release Solid Oral
Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing
and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence
Documentation [Электронный ресурс] // US FDA, CDER. – 1995. – Режим
доступа: www.fda.gov/regulatory-information/search-fda-guidance-documents/
supac-ir-immediate-release-solid-oral-dosage-forms-scale-and-post-approval-
changes-chemistry.
314. Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage
Forms [Электронный ресурс]// Food and Drug administration. – 1997. – Режим
378
Достарыңызбен бөлісу: